Canopy Growth (WEED.TO) (TWMJF) has rallied 25% off its June lows and the shares have been trending higher ahead of the company’s fourth quarter and full-year earnings report.
Before the market opens on June 27th, Canopy will release its fourth quarter financial and operating results and we expect to see the company report strong numbers for the period.
Last week, Canopy Growth provided shareholders with a corporate update and the market responded very favorably to this update.
A Global Expansion Story
From Germany to Australia, this Canadian licensed medical marijuana producer continues to increase market share across the globe and we expect this to trend continue as management continues to execute.
Canopy announced that it is renaming its German subsidiary to Spektrum Cannabis Germany GmbH and confirmed ongoing sales of Tweed-branded products in Germany with sales growth accelerating rapidly on a month-over-month basis. Spektrum Cannabis Germany GmbH has now distributed cannabis products to over 480 pharmacies across Germany, up from 200 pharmacies in April 2017.
The company also established a new subsidiary for its entrance into Chile’s market, Spectrum Chile SpA. Canopy will enter this market with the creation of a new product, Spectrum Chile. This product will complement Canopy’s expansion into South America and Canopy Growth plans to position itself as a leader in the Chilean market.
Through a strategic partnership with a domestic Chilean medical cannabis company, Spectrum Chile will work to ensure Chilean patients have access to high-quality cannabis products.
A Company of Firsts
Canopy Growth has been a leader in the global cannabis market and the company has benefited from having a first mover advantage.
In April 2014, Canopy Growth became the first cannabis company in North America to be publicly traded. The company followed was also the first to diversify its platform to include both greenhouse and indoor growing, to acquire a major competitor and to be listed on the Toronto Stock Exchange, and the only cannabis company to be a member of a major global stock market index (S&P/TSX Composite index).
Canopy was the first Canadian producer to be approved to export dried cannabis to Germany through its Tweed subsidiary, and its wholly-owned German subsidiary continues to offer several varieties for sale through German pharmacies.
Canopy recorded another milestone this month by becoming the first company to start selling softgel capsules in Canada. This product offers consumers a new way to consume cannabis and they are being produced at Canopy’s Smiths Falls campus. Canopy will offer this product through the Tweed Main Street store, which serves over 58,000 customers.
A Favorable Outlook
We are favorable on Canopy Growth Corp due to the following reasons: 1) It is the largest and best capitalized medical cannabis producer, 2) The company continues to execute on its initiatives and work toward creating value for its shareholders, 3) Management has a proven track record of success, 4) The company continues to report earnings that show improving fundamentals, and 5) Its balance sheet is flush with cash and leaves the company flexible and able to expand through both organic and inorganic growth initiatives.
Authored By: Jason Spatafora